Studies show benefits of immediate antiretroviral treatment for HIV-infected infants
Results from two studies presented today at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle demonstrate the importance of identifying and treating HIV-infected infants within the first year of life both to prevent harm to the immune system and to enable normal neurological development.
Although immediate ART during infancy benefits HIV-infected babies, the prospect of lifelong treatment raises numerous concerns, including the risk of drug side effects and the potential for resistance to develop to available treatments. The "Children with HIV Early Antiretroviral Therapy" (CHER) trial, funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, launched in South Africa in 2005. It tested a novel strategy of giving immediate ART to HIV-infected infants (babies under 3 months of age) but stopping it after the period of infancy when the risks of consequences from HIV and other infections decreases. Treatment was not resumed until there was some evidence of health decline. The study initially compared immediate versus delayed treatment, but the delayed treatment arm was stopped in 2007 after a data and safety monitoring board found that infants given ART beginning at an average age of 7 weeks had a significantly lower risk of death within 48 weeks compared with infants in the deferred treatment group. Based on these findings, in 2008 the World Health Organization revised its treatment guidelines to recommend that in HIV-infected children under the age of one, ART be started immediately after HIV diagnosis, regardless of their state of health.
Study results presented today by Mark Cotton, M.D., Ph.D., of Stellenbosch University in South Africa, showed that infants could safely stop ART after 1 to 2 years and continue to fare significantly better than those infants in whom the initiation of therapy was delayed until signs of illness or a weakened immune system appeared. Importantly, very few infants who received immediate ART had significant disease progression or died after treatment was stopped. Many of the infants who stopped therapy were able to remain off treatment for a long time. In follow up of the 375 study participants, 33 percent of infants who received 2 years of initial ART and 25 percent of the infants who received 1 year of initial therapy were still well and, therefore, able to remain off treatment for roughly 5 years after the study officially ended.
Another presentation highlighted new results from the PREDICT study. This Phase III clinical trial among HIV-infected children in Thailand and Cambodia examined the question of when to begin ART in children who were not diagnosed with HIV during infancy and, therefore, did not present for medical treatment until they became mild to moderately sick. The study, which began in 2006 and involved 299 children ages 2 to 12, compared beginning treatment immediately or delaying treatment until levels of CD4+ T cells, a key indication of immune system health, fell to a certain threshold. Jintanat Ananworanich, M.D., Ph.D., of the HIVNAT Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, presented findings at CROI today demonstrating that both study groups experienced comparably low rates of disease progression, while higher rates of drug toxicities and resistance were found in the immediate treatment group. Neurological development problems were frequent and equally prevalent in both groups.
Taken together, both the CHER and PREDICT studies illustrate the importance of identifying and treating HIV-infected infants as soon as possible to preserve the immune system and ensure healthy brain development. If the treatment in infancy window is missed, ART in older HIV-infected children, whether begun immediately or delayed, can still provide comparable health benefits but it does not prevent or reverse neurological damage.
More information: Findings from both studies were presented today at the 19th Conference on Retroviruses and Opportunistic Infections at the Washington State Convention Center in Seattle.
Provided by National Institutes of Health
-
Landmark study defines benefits of early HIV testing and treatment for infected infants
Nov 19, 2008 |
not rated yet |
0
-
Treating HIV-infected infants early helps them live longer
Jul 25, 2007 |
not rated yet |
0
-
Study suggests early ART in recently HIV-infected patients preferable to delayed treatment
Dec 16, 2011 |
not rated yet |
0
-
Scientists find more health benefits from starting HIV treatment early
Sep 28, 2010 |
not rated yet |
0
-
NIH studies influence revision of WHO guidelines for treating HIV-infected women, infants
Oct 13, 2010 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Fecal microbiota tx feasible for recurrent C. difficile in HIV
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...
HIV & AIDS
56 minutes ago |
not rated yet |
0
Canada lifts ban on gay men donating blood
Canadian health authorities lifted Wednesday what was effectively a ban on gay men giving blood, announcing new rules making men who have not had sex with men in the past five years eligible.
HIV & AIDS
2 hours ago |
not rated yet |
0
AIDS scientists optimistic of AIDS cure, for some
Top AIDS scientists were optimistic Wednesday of finding a cure for the disease that has claimed 30 million lives—but said it might not work for all people.
HIV & AIDS
5 hours ago |
not rated yet |
0
Integrating mental health care into HIV care
The integration of mental health interventions into HIV prevention and treatment platforms can reduce the opportunity costs of care and improve treatment outcomes, argues a new Policy Forum article published in this week's ...
HIV & AIDS
May 21, 2013 |
not rated yet |
0
After a decade, global AIDS program looks ahead
(AP)—The decade-old law that transformed the battle against HIV and AIDS in developing countries is at a crossroads. The dream of future generations freed from the epidemic is running up against an era ...
HIV & AIDS
May 21, 2013 |
not rated yet |
0
Calorie information in fast food restaurants used by 40 percent of 9-18 year olds when making food choices
A new study published online today (Thursday) in the Journal of Public Health has found that of young people who visited fast food or chain restaurants in the U.S. in 2010, girls and youth who were obese were more likely ...
Having both migraines, depression may mean smaller brain
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Brain can be trained in compassion, study shows
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
Slowing the aging process—only with antibiotics
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
Systematic screening of med adherence will ID barriers
(HealthDay)—Implementation of systematic monitoring for medication adherence will allow for identification of barriers to adherence and tailoring of interventions, according to a viewpoint piece published ...